News Conference News EAS 2022 Stepwise or Hammer Down? Experts Debate Best Approach to LDL-Lowering Michael O'Riordan May 24, 2022
News Conference News ESC 2017 CANTOS: Anti-inflammatory Agent Canakinumab Modestly Reduces Major CVD Events Michael O'Riordan August 27, 2017
News Daily News Pharmacist Management of High Cholesterol Gets More Patients to Goal, Lowers LDL Levels: RxACT Michael O'Riordan September 29, 2016
News Daily News Lowering LDL With Statins and Other Selected Agents Should Be Focus of CVD Risk Reduction, Analysis Implies Michael O'Riordan September 27, 2016
News Conference News ESC 2016 Focus on LDL Cholesterol Targets With Statin Therapy, New ESC-EAS Cholesterol Guidelines Say Michael O'Riordan August 27, 2016
News Daily News ‘Lower Is Better’ Mantra for LDL Cholesterol Questioned by New Analysis, but Experts Urge Caution Todd Neale June 22, 2016
News Daily News Detection and Treatment of Severe FH Depends on LDL Levels, Not Genes, Says Expert Panel Michael O'Riordan June 09, 2016
News Conference News EAS 2016 Preservation of LDL Cholesterol Targets for Lipid Lowering in New European Guidance Gets Blessing of Prevention Experts Yael L. Maxwell June 06, 2016
News Daily News ACC Updates LDL-Cholesterol Lowering Recommendations, Making Room for Ezetimibe and PCSK9 Inhibitors Michael O'Riordan April 02, 2016
News Daily News Data Support Treating Patient Risk, Not LDL Cholesterol Targets, Paper Argues Michael O'Riordan February 15, 2016
News Daily News NHANES: Just Over Half of Eligible Patients Taking Cholesterol-Lowering Medication Michael O'Riordan December 08, 2015
News Industry News Regeneron and Sanofi Announce Approval of Praluent® (alirocumab) for the Treatment of Hypercholesterolemia in the European Union September 28, 2015
News Industry News Positive Clinical Data From Lp(a) Lowering Drug ISIS-APO(a) Rx Published in The Lancet July 23, 2015